Ixekizumab, An Effective Biologic Agent Therapy in Various Cases of Psoriasis: A Narrative Review
Keywords:
Psoriasis, IL-17 Inhibitor, Ixekizumab, Biologic AgentAbstract
Psoriasis is a chronic inflammatory skin condition with immune involvement, characterized by skin inflammation and epidermal hyperplasia, increased risk of arthritis, cardiovascular disorders, and psychosocial burden. In the current management of psoriasis, the use of biologic therapy is increasingly being studied. This paper is aimed to increase understanding of ixekizumab in psoriasis management, so that its utilization can be optimized. Currently, the main biological agents have action on two crucial pathways in the psoriasis development and its chronicity, namely the IL-23/Th17 pathway and the TNF-? signaling pathway. Biological agents targeting the IL-17 receptor have shown higher efficacy and safety compared to those targeting TNF-? and IL-23 receptors in treating moderate to severe plaque-type psoriasis. Ixekizumab, one of the selective IL-17A pathway inhibitor, plays a crucial role in managing the occurrence of psoriasis. FDA has approved the use of ixekizumab for moderate to severe psoriasis (PsO) and psoriatic arthritis (PsA) . Numerous clinical trials have demonstrated the safety and efficacy of ixekizumab in treating both plaque psoriasis and PsA. The side effects are generally mild, in the form of nasopharyngitis, pain at the injection site, and upper respiratory tract infections.References
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1–28.
Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatology. 2021;157(8):940–6.
Sanclemente G, Mora O, Velez N, Diaz CJ, Que-vedo E, Amador J, et al. Epidemiologic characte-ristics and burden of psoriasis: A multicenter, cross – sectional study. Medwave. 2022;22(8): e002564.
Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz I Bin, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors uste-kinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Derma-tolog Treat [Internet]. 2018;29(6):569–78. Available from: https://doi.org/10.1080/09546634.2017.1422591
Gudjonsson, Johan E, Elder J. Psoriasis. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, LD PA, edi-tors. Fitzpatricks Dermatology in General Medi-cine. 2019. p. 491–531.
Bozek A, Reich A. The reliability of three psoriasis assessment tools: Psoriasis area and severity in-dex, body surface area and physician global asse-ssment. Adv Clin Exp Med. 2017;26(5):851–6.
Alcusky M, Lee S, Lau G, Chiu GR, Hadker N, Deshpande A, et al. Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis. Dermatol Ther (Heidelb). 2017; 7(4):463–83.
British Association of Dermatologists. PSORIASIS Area and Severity Index (PASI) Worksheet. p. 4.
Canadian Agency for Drugs and Technologies in Health. CDR Clinical Review Report for Revolade. 2014; (October). Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0088036/
Diotallevi F, Campanati A, Radi G, Molinelli E, Offidani A. Ixekizumab for treatment of moderate to severe plaque psoriasis: real world clinical exp-erience. G Ital di Dermatologia e Venereol. 2020; 155(6):739–43.
Eldirany SA, Ho M, Bunick CG. Structural basis for how biologic medicines binds their targets in psoriasis therapy. Yale J Biol Med. 2020;93(1):19–27.
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 Trials of Ixek-izumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016;375(4):345–56.
Chiricozzi A, Burlando M, Caldarola G, Conti A, Damiani G, De Simone C, et al. Ixekizumab Effe-ctiveness and Safety in the Treatment of Mode-rate-to-Severe Plaque Psoriasis: A Multicenter, Re-trospective Observational Study. Am J Clin Der-matol [Internet]. 2020;21(3):441–7. Available from: https://doi.org/10.1007/s40257-019-00490-2
Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355–62.
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of pso-riasis with biologics. J Am Acad Dermatol [Inter-net]. 2019;80(4):1029–72. Available from: https://doi.org/10.1016/j.jaad.2018.11.057
Tobergte DR, Curtis S. Highlights of Prescribing Information These highlights do not include all the information needed to use TALTZ safely and effectively. See full prescribing information for TALTZ. J Chem Inf Model. 2013;53(9):1689–99.
Deodhar AA, Combe B, Accioly AP, Bolce R, Zhu D, Gellett AM, et al. Safety of ixekizumab in pati-ents with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure. Ann Rheum Dis. 2022;81(7):944–50.
Griffiths CEM, Gooderham M, Colombel JF, Terui T, Accioly AP, Gallo G, et al. Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Pso-riasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. Dermatol Ther (Heidelb) [Internet]. 2022;12(6):1431–46. Available from: https://doi.org/10.1007/s13555-022-00743-9
Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, Martínez-García EA, Herrera-Ceballos E. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-sev-ere psoriasis after 1 year of treatment: Real-world practice. Dermatol Ther. 2020;33(3):5–10.
Rivera R, Velasco M, Vidal D, Carrascosa JM, Dau-dén E, Vilarrasa E, et al. The effectiveness and saf-ety of ixekizumab in psoriasis patients under cli-nical practice conditions: A Spanish multicentre retrospective study. Dermatol Ther. 2020;33(6):6–12.
Serrano L, Carlberg V, Holland K. Rapid Efficacy of Ixekizumab for Pediatric Acute Generalized Pustular Psoriasis. Natl Soc Cutan Med. 2021;5(6): 667–71.
Nagata M, Kamata M, Fukaya S, Hayashi K, Fuk-uyasu A, Tanaka T, et al. Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab. J Am Acad Dermatol. 2020;82(3):758–61.
Egawa G, Honda T, Kabashima K. Long-term effi-cacy of ixekizumab in erythrodermic and generali-zed pustular psoriasis patients. J Eur Acad Der-matology Venereol. 2019;33(2):259.
